These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30379088)

  • 21. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
    Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
    Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
    Eskander RN; Tewari KS
    Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
    Santos LV; Cruz MR; Lopes Gde L; Lima JP
    Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation.
    Clément-Zhao A; Tanguy ML; Cottu P; De La Lande B; Bontemps P; Lemanski C; Baumann P; Savignoni A; Levy C; Peignaux K; Reynaud-Bougnoux A; Gobillion A; Kirova Y
    PLoS One; 2019; 14(8):e0221816. PubMed ID: 31469859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiangiogenic Therapy in Colorectal Cancer.
    Mody K; Baldeo C; Bekaii-Saab T
    Cancer J; 2018; 24(4):165-170. PubMed ID: 30119079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
    Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland.
    Chapman SJ; McKavanagh D; Burge ME; McPherson I; Walpole E; Hollingworth SA
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e253-e261. PubMed ID: 27435535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
    Minion LE; Tewari KS
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Graham CN; Christodoulopoulou A; Knox HN; Sabatelli L; Hechmati G; Garawin T; Strickler JH
    J Med Econ; 2018 Nov; 21(11):1075-1083. PubMed ID: 30091652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
    Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
    Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab in advanced lung cancer: state of the art.
    Assoun S; Brosseau S; Steinmetz C; Gounant V; Zalcman G
    Future Oncol; 2017 Dec; 13(28):2515-2535. PubMed ID: 28812378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?
    Eskens FA; Sleijfer S
    Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Ruan WC; Che YP; Ding L; Li HF
    Comb Chem High Throughput Screen; 2018; 21(10):718-724. PubMed ID: 30663563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.
    Khmamouche MR; Mahfoud T; Bazine A; Tanz R; Ichou M; Errihani H
    Pan Afr Med J; 2016; 25():118. PubMed ID: 28292081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis.
    Chebib R; Verlingue L; Cozic N; Faron M; Burtin P; Boige V; Hollebecque A; Malka D
    Semin Oncol; 2017 Apr; 44(2):114-128. PubMed ID: 28923209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.